Zobrazeno 1 - 10
of 54
pro vyhledávání: '"M. Müngersdorf"'
Autor:
B. Haslinger, Pascal Maisonobe, A. Stenner, M. Müngersdorf, Wolfgang H. Jost, A. Schramm, M. Koch, P. Schwingenschuh
Publikováno v:
Journal of the Neurological Sciences. 399:44-50
AbobotulinumtoxinA (aboBoNT-A; Dysport®) is an effective treatment for cervical dystonia (CD) with a well-established safety profile. In this prospective, multicentre, non-interventional study ( NCT01840462 ) the primary objective was effectiveness
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0e5bcede25ae9a5e686bb636c80b4e4f
https://doi.org/10.1016/j.jns.2019.02.017
https://doi.org/10.1016/j.jns.2019.02.017
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Aktuelle Neurologie. 40:333-337
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f7f4b4361c1908f95a283ea7b24e8e5
https://doi.org/10.1055/s-0033-1343459
https://doi.org/10.1055/s-0033-1343459
Autor:
A. Christopher, I. Dodel, M. Müngersdorf, W. H. Oertel, H. Friedrich, R. Puzich, Jens P. Reese, Siefjediers, R. Ehret, S. Kraemer, Monika Balzer-Geldsetzer, Richard Dodel, K. Tiel-Wilck, I. Schultes-Platzek, W. Lüer, A. Rohr, E. Becker
Publikováno v:
Der Nervenarzt. 80:452-458
BACKGROUND Aim of this study was to assess the direct costs of Parkinson's disease (PD) within a 3-month period (i.e. the accounting period for the German statutory health insurance) in 12 neurological outpatient practices in Berlin during 2006. MATE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e62c835253a505e709d033c9cd620d66
https://doi.org/10.1007/s00115-009-2671-y
https://doi.org/10.1007/s00115-009-2671-y
Publikováno v:
Journal of Clinical Neuroscience. 9:521-524
The study aimed to compare olfactory function in idiopathic Parkinson's disease (IPD) and nonidiopathic Parkinson's syndrome (PS). At their first visit 50 PS patients (age 38-80 years) received testing for odor threshold, olfactory discrimination and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a6e782a490c66a827b57db4e07141214
https://doi.org/10.1054/jocn.2001.1071
https://doi.org/10.1054/jocn.2001.1071
Publikováno v:
Aktuelle Neurologie. 38:552-554
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::dd47b98716587c235a8206d2d3790102
https://doi.org/10.1055/s-0031-1301278
https://doi.org/10.1055/s-0031-1301278
Publikováno v:
Journal of Neural Transmission. 108:1309-1317
Ropinirole is effective as mono- and combination therapy in PD. Previous studies have used a maximal dose of 24 mg/day; the present study assesses the effect of higher doses (up to 36 mg/day) on patients with motor fluctuations. Outcome measures were
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c24b54257a726a3af31c88698e0b5a1b
https://doi.org/10.1007/s007020100007
https://doi.org/10.1007/s007020100007
Autor:
M. Müngersdorf, H. Reichmann
Publikováno v:
Der Internist. 40:83-93
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::5ca7ac9246c06b37ee6e62fcbf94e3d2
https://doi.org/10.1007/s001080050311
https://doi.org/10.1007/s001080050311